Member Info for mulledwine

Mike Hodgson, Chief Executive, commented: "We are confident that the existing Palito gold resource extends towards the Espeto prospect located some 800 metres to the south east, and with Curretela a further 900 metres along strike, the potential continues. In late 2008 we undertook some additional drilling which showed significant extension to the current limit of the Palito resource by some 500 metres and this new drilling not only supports this, but adds a further 300 metres. If this is substantiated by further resource drilling it would more add some 80% to the strike length of the current Palito resource. The grades are of course very pleasing and suggest that the high grade nature of the ore that makes Palito such a compelling opportunity continue along the mineralized zone. The relative shallowness of the intersections (mostly between 45 metres and 80 metres vertical depth) is also indicative of the possibility to initially use open pit mining methods which can reduce the complexity and risk of future mining operations."

Bonanza Gold Grades Returned from Palito Extension Drilling Serabi Gold plc (AIM:SRB, TSX:SBI and SBI.WT), the Brazilian focused gold exploration company, is pleased to announce encouraging preliminary analytical results from shallow extension drilling on the south-eastern strike extension of the Palito deposit have returned Bonanza grade gold and high grade copper results Preliminary analytical results set out below from shallow infill and step out drilling on the strike extension of the Palito Main Zone have been returned from the onsite analytical laboratory at the Palito mine (see footnote - Preliminary Assay Results). Drilling commenced in late October on the shallow depth projection of several interpreted higher grade mineralized shoots and was completed in mid-November. The program completed a total of 8 holes for a total of 937m of shallow diamond drill holes (PDD0519-PDD0526). Preliminary assays for the first five of these holes have now been received. All eight holes have been sampled, and submitted to the Company's primary laboratory at ALS Chemex in Vancouver. The results of this final analysis will be released in due course.

http://www.investegate.co.uk/Article.aspx?id=20111124070026H6260

not good reading but how much is already priced in

Peter Allen, Future's Chairman, said: "Given the decline in Group performance and profitability, the Board took action to remove corporate level cost and change the way the company is managed. We have installed as new Group CEO and Finance Director, two individuals with a proven track record of running an efficient business for Future in the UK and achieving rapid and profitable digital transformation." Mark Wood, Future's Chief Executive, said: "Building on the digital success in the UK, we have taken steps to reorganise the company, merge UK and US operations and create a single global product line. These changes will enable us to operate more efficiently and return the US business to profitability. The changes will also mean that we can accelerate our transition to a digital business model and start to sell our entire range of digital content to high-value audiences in the US and other key markets. "Digital channels such as the Apple iPad are rapidly opening up new routes to markets in which our niche products can quickly build a loyal following. Future's success on the Apple Newsstand, with more than six million downloads of our apps in a month, has demonstrated our ability to develop and deliver digital products at high speed, and underlines the global appeal of content ranging from Cycling, Games and Technology to Music, Film and Crafts. So, as a result, we look forward to the year ahead with confidence."

Financial and operating headlines: · UK delivers resilient performance: strong digital revenue growth (up 36%) offsets managed decline in print revenues · US: significant loss driven by print - measures are in place to reduce scale of exposure and return US to profitability by 2013 · Net debt increased by £4.4m to £11.8m · Extension of bank facility by 12 months to November 2013, to provide flexibility for ongoing restructuring programme in FY12 · Dividend holiday to conserve cash/strengthen balance sheet - expected to resume payment in 2013 · Operating costs reducing by an estimated annualised £4.5m by end of FY12 · Changes in top-level management and focus - and removal of corporate costs · Restructuring in UK complete, but ongoing in US - further exceptionals in FY12 · Merger of two businesses to create integrated product line · Launched over 100 digital titles for tablet devices - encouraging trends, six million Apple Newsstand app downloads in first month

http://www.investegate.co.uk/Article.aspx?id=201111240700276808S

Mr Tim Sharpington, CEO commented: "Over the past year we have refocused the business and have made good progress in the development of our pharmaceutical programmes. Our lead programme, CoganeTM in Parkinson's disease, is on track to complete patient recruitment in its Phase II clinical trial in spring 2012. We have received encouraging data in our follow-up programmes in both ALS and glaucoma and expect further results in Q1 2012. Importantly, we also secured Orphan Drug Status for Cogane™ in ALS in both the USA and EU. Our projects have the potential to be major treatment advances for these indications and have attracted favourable attention from opinion leaders and patient groups involved with the treatment of these diseases. We look forward to receiving the results from our ongoing studies."

Preliminary Results Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") announces today its preliminary results for the year ended 30 September 2011. Business highlights Operational · Cogane™ Phase II Parkinson's disease trial (CONFIDENT-PD) on track to complete recruitment in spring 2012 with results around the end of 2012 · Positive preclinical results on Cogane™ in Parkinson's disease presented at the Movement Disorders Conference in June 2011 · Cogane secures Orphan Drug status from US Food & Drug Administration and the European Commission for the treatment of amyotrophic lateral sclerosis · Positive data achieved in preclinical model of ALS with Cogane™. Initiated "gold standard" genetic in vivo model with the financial support of the UK Motor Neurone Disease Association; results anticipated in Q1 2012 · Encouraging early data reported from the recently initiated programme investigating the effect of Myogane™ in glaucoma. Further results due in Q1 2012 · Technology Strategy Board provided grant funding to support the development of Myogane™ in glaucoma · P61 anti-inflammatory project re-activated, lead compound selected for further development Financial · Loss after tax increased to £7.66 million in line with expectations reflecting increased focus on the development of our pharmaceutical programmes (FY 2010: £3.80 million) · Cash and money market investments of £17.57 million (FY 2010: £23.61 million)

http://www.investegate.co.uk/Article.aspx?id=201111240700206717S

Seymour Pierce has reiterated its buy rating and 650p target for contract caterer Compass following the group's full-year results. "The outlook is positive and we expect Compass to continue to improve organic growth and margin," Seymour Pierce said.

UBS has downgraded Meggitt from neutral to sell after cutting back its earnings forecasts for this year and the next. "Meggitt has also outperformed the European aftermarket stocks by 12% over the last three months and is within 7% of its all time high. Meggitt is on the UBS M&A watch list," the broker said. The target price was cut from 340p to 330p.

Security products company Croma Group (CMG) achieved 67% growth in revenue in the year ended 30th June as it completed the final stage of its restructuring and broadened its customer offerings. Profits for the period stood at 116,000 pounds, a vast improvement from a 5,600 pound. The company was however forced to reported to 626,000 pound comprehensive loss after writing off goodwill of 742,000 pounds from discontinued operations. Croma shares added 0.075p to close at 1.85p.

wotreally - you seem to have had a good day today in here ...GL

PSG Solutions (PGS), the specialist electronics company, reported pre-tax profits of 3.86 million pounds in the six months ended 30th September, up from a 315,000 pound loss in the previous period. The substantially improved financial results were thanks to a major contract award from a government agency, worth 48.7 million pounds. In order to facilitate the project, due in October 2012, the company has leased out a 30,000 square foot premises and installed production lines. The shares leapt 9.5p to 119.5p

Earthport (EPO) was another company to release full-year results, this time for the period ended 30th June, in which losses widened 48% to 7.5 million pounds despite a 28% rise in revenue to 2.5 million pounds. The global payments group realised significantly higher administrative costs following additions to the board and senior management as well as a notable share based payment charge after raising 7.5 million pounds via a secondary issue. The board is confident the firm is well positioned to benefit from high volume cross-border payments in the near future, and believe the company is "at an exciting point in its evolution". The shares dropped 1.125p to 17.5p.

Evolution Securities reiterated its "buy" recommendation for Morgan Crucible (MGCR) with a target price of 370p. The broker believes that the market has not fairly valued the potential of the carbon and ceramic products manufacturer's Superwool product. Superwool is progressively replacing refractroy ceramic fibre, and Evolution notes that it is already more commonly used in Europe that RCF. While Morgan has a 30% share in the RCF market, it has a 60% marketshare of Superwool and as the product becomes more popular globally, the broker expects the firm to benefit from higher profit margins. The shares tumbled 9.6p to 233.4p.

MAM Funds (MMF) kept its "strong buy" rating from Arbuthnot Securities, with a 42p target price. The broker says that the investment manager has performed very well in 2011, relative to its competitors. With its largest fund having a conservative strategy, Arbuthnot notes that it has seen good inflows this year as investors look for safe havens. The broker believes that this year presents an opportunity for the management to secure better distribution channels and expects to see an increase in profitability in the near future. MAM shares were unchanged at 20.75p.

Shore Capital maintained its "buy" recommendation for Shire Pharmaceuticals (SHP) which has submitted filings in the US an Europe for the production of its Gaucher's disease treatment VPRIV. Additionally, with the group's competitor Genzyme suffering from production delays, the broker believes Shire is well positioned to take advantage of supply shortages. Shares in Shire edged up 15p to 2,010p.

Halma: UBS reduces target from 325p to 300p, sell rating unchanged